Collaborate in Minimal Residual Disease Assessment
We are always on the lookout for collaborators.
Whether you’re part of an academic research group, an innovative biotech start-up, a pharmaceutical company, or a contract research organization (CRO), we want to hear from you. If you’re excited about advancing blood-based cancer diagnostics, circulating tumor DNA (ctDNA) technologies, or highly sensitive minimal residual disease (MRD) monitoring across cancer types, including lymphoma and solid tumors, LIQOMICS is your ideal partner.
Our expertise lies in next-generation liquid biopsy solutions that provide precise tumor genotyping and longitudinal tracking of ctDNA for translational research and drug development. From early discovery through clinical trials, we work closely with pharma and CRO partners to deliver high-resolution molecular insights using just a blood sample. For academic labs, we offer access to state-of-the-art ctDNA profiling tools to support novel biomarker discovery and clinical research.
Get in contact with us and let us explore how we can team up to push the boundaries of cancer genomics together.
